| 1. |
Robenshtok E,Gafter-Gvili A,Goldberg E,et al.Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation:systematic review and meta-analysis.J Clin Oncol,2007,25(34):5471-5489.
|
| 2. |
Marks DI,Kibbler C,Pagliugi A,et al.Voriconazole vs Itraconazole for primary prophylaxis of invasive fungal infection in allogeneic hematopoietic cell transplant (HCT) recipients.In:49th Interscience Conference on Antimicrobial Agents and Chemotherapy;2009;San Francisco,CA 2009.
|
| 3. |
Ullmann AJ,Lipton JH,Vesole DH,et al.Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.N Engl J Med,2007,356(4):335-347.
|
| 4. |
Wingard JR,Carter SL,Walsh TJ,et al.Results of a randomized,double-blind trial of Fluconazole vs.Voriconazole for the prevention of invasive fungal infections in 600 allogeneic blood and marrow transplant patients.In:49th American Society of Hematology Annual Meeting and Exposition,American Society of Hematology:Atlanta,GA,2007,163.
|
| 5. |
Rijnders BJ,Cornelissen JJ,Slobbe L,et al.Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia:a randomized,placebo-controlled trial.Clin Infect Dis,2008,46(9):1401-1408.
|
| 6. |
Fukuda T,Boeckh M,Guthrie K,et al.Invasive aspergillosis before allogeneic hematopoetic stem cell transplantation:10 year experience at a single transplant center.Biol Bone Marrow Transplant,2004,10(7):494-503.
|
| 7. |
Martino R,Parody R,Fukuda T,et al.Impact of the intensity of the pretransplant conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation:a retrospective survey of the infectious diseases working party of the European Group for Blood and Marrow Transplantation.Blood,2006,108(9):2928-2936.
|
| 8. |
Cordonnier C,Rovira M,Maertens J,et al.Voriconazole for secondary prophylaxis of invasive fungal infection in allogeneic stem cell transplant recipients:results of the VOSIFI study.Haematologica,2010,95(10):1762-1768.
|
| 9. |
Maertens JA1,Madero L,Reilly AF,et al.A randomized,double-blind,multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia.Pediatr Infect Dis J,2010,29(5):415-420.
|
| 10. |
Kubiak X.Caspofungin vs micafungin for empirical therapy in adult neutropenic patients with persistent fever:a retrospective analysis.In:48th ICAAC;2008.Washington,DC,2008.
|
| 11. |
Ohta K,Kosaka SN,Nakao Y,et al.Efficacy and safety of intravenous itraconazole as empirical antifungal therapy for persistent fever in neutropenic patients with hematological malignancies in Japan.Int J Hematol,2009,89(5):649-655.
|
| 12. |
Walsh TJ,Finberg RW,Arndt C,et al.Liposomal Amphotericin B for empirical therapy in patients with persistent fever and neutropenia.N Engl J Med,1999,340(10):764-771.
|
| 13. |
Walsh TJ,Teppler H,Donowitz GR,et al.Caspofungin versus liposomal Amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.N Engl J Med,2004,351(14):1391-1402.
|
| 14. |
Maertens J,Theunissen K,Verhoef G,et al.Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection:a prospective feasibility study.Clin Infect Dis,2005,41(9):1242-1250.
|
| 15. |
Hebart H,Klingspor L,Klingebiel T,et al.A prospective ranomized controlled trial comparing PCR-based and empirical treatment with liposomalamphotericin B in patients after allogeneic stem cell transplant.Bone Marrow Transplant,2009,43(7):553-561.
|
| 16. |
Cordonnier C,Pautas C,Maury S,et al.Empirical versus pre-emptive antifungal strategy in high-risk febrile neutropenic patients:a prospective randomized study.Clin Infect Dis,2009,48(8):1042-1051.
|
| 17. |
Riva E,Nosari A,Brizio A,et al.In high risk acute leukemia patients,early antifungaltherapy improves the outcome of invasive mould infections.In:48th Interscience Conference on Antimicrobial Agents and Chemotherapy;2008,Chicago,2008.
|
| 18. |
Aguilar-Guisado M,Espigado I,Cordero E,et al.Empirical antifungal therapy in selected patients with persistent febrile neutropenia.Bone Marrow Transplant,2010,45(1):159-164.
|
| 19. |
Barnes RA,White PL,Bygrave C,et al.Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients.J Clin Pathol,2009,62(1):64-69.
|
| 20. |
Dignan FL,Evans SO,Ethell ME,et al.An early CT-diagnosis based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line:an effective strategy with low mortality.Bone Marrow Transplant,2009,44(1):51-56.
|
| 21. |
Girmenia C,Micozzi A,Gentile G,et al.Clinically driven diagnostic antifungal approach in neutropenic patients:a prospective feasibility study.J Clin Oncol,2010,28(4):667-674.
|
| 22. |
Herbrecht R,Maertens J,Baila L,et al.Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients:a European Organisation for Research and Treatment of Cancer study.Bone Marrow Transplant,2010,45(7):1227-1233.
|
| 23. |
Viscoli C,Herbrecht R,Akan H,et al.An EORTC Phase Ⅱ study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients.J Antimicrob Chemother,2009,64(6):1274-1281.
|
| 24. |
Hachem RY,Boktour MR,Hanna HA,et al.Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.Cancer,2008,112(6):1282-1287.
|
| 25. |
Cesaro S,Giacchino M,Locatelli F,et al.Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients.BMC Infect Dis,2007,7:28.
|
| 26. |
Betts RF,Nucci M,Talwar D,et al.A multicenter,double-blind trial of a highdose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis.Clin Infect Dis,2009,48(12):1676-1684.
|
| 27. |
Brouwers MC,Kho ME,Browman GP,et al.AGREE Ⅱ:advancing guideline development,reporting,and evaluation in health care.Prev Med,2010,51(5):421-424.
|
